Olamkicept

Olamkicept (FE 999301) is a selective inhibitor of the soluble interleukin 6 ( sIL-6R )/ IL-6 complex. Olamkicept is a soluble gp130-Fc-fusion-protein and anti-inflammatory agent In Vitro Olamkicept (10 µg/mL, 60 min) inhibits IL-6 trans-signaling mediated STAT3 activation in HRECs . Olamkicept (10 µg/mL, 60 min) inhibits IL-6 trans-signaling induced increase in H 2 O 2 levels in HRECs . Olamkicept (10 µg/mL, 60 min) inhibits IL-6 trans-signaling induced apoptosis in HRECs . Olamkicept (0-1 µg/mL) inhibits IL-11/recombinant sIL-11R induced proliferation of Ba/F3-gp130 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis Cell Line: Human retinal endothelial cells (HRECs) Concentration: 10 µg/mL Incubation Time: 60 min Result: Inhibited IL-6/sIL-6R induced increase in STAT3 phosphorylation. In Vivo Olamkicept (sgp130Fc) (0.01-10 mg/kg, s.c.) increases survival in a cecal ligation and puncture (CLP) sepsis mice model. Olamkicept (0.5 mg/kg, i.p.) suppresses inflammation and increases survival rate in cecum ligation and puncture (CLP)-induced mice with sepsis. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Cecal ligation and puncture (CLP) sepsis mice modelDosage: 0.01, 0.1, 1, 10 mg/kg Administration: s.c. Result: Improved survival rate and physical activity. IC50& Target:sIL-6R/IL-6 Complex

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet